Key Updates on CymaBay’s Lead Product Candidate
CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.